Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

被引:36
|
作者
Del Prete, Gregory Q. [1 ]
Lifson, Jeffrey D. [1 ]
Keele, Brandon F. [1 ]
机构
[1] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Leidos Biomed Res Inc, Frederick, MD USA
基金
美国国家卫生研究院;
关键词
macaque; simian-human immunodeficiency virus; simian immunodeficiency virus; vaccine challenge; SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS MACAQUES; MENSTRUAL-CYCLE; NEUTRALIZATION SENSITIVITY; DISEASE PROGRESSION; CYNOMOLGUS MACAQUES; PARTIAL PROTECTION; SIV CHALLENGES; INFECTION; SHIV;
D O I
10.1097/COH.0000000000000311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewNonhuman primate (NHP) models of AIDS are powerful systems for evaluating HIV vaccine approaches in vivo. Authentic features of HIV-1 transmission, dissemination, target cell tropism, and pathogenesis, and aspects of anti-HIV-1 immune responses, can be recapitulated in NHPs provided the appropriate, specific model parameters are considered. Here, we discuss key model parameter options and their implications for HIV-1 vaccine evaluation.Recent findingsWith the availability of several different NHP host species/subspecies, different challenge viruses and challenge stock production methods, and various challenge routes and schemata, multiple NHP models of AIDS exist for HIV vaccine evaluation. The recent development of multiple new challenge viruses, including chimeric simian-human immunodeficiency viruses and simian immunodeficiency virus clones, improved characterization of challenge stocks and production methods, and increased insight into specific challenge parameters have resulted in an increase in the number of available models and a better understanding of the implications of specific study design choices.SummaryRecent progress and technical developments promise new insights into basic disease mechanisms and improved models for better preclinical evaluation of interventions to prevent HIV transmission.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 50 条
  • [11] Progress in the development of a preventive HIV-1 vaccine
    Elizaga, ML
    McElrath, MJ
    CLINICS IN LABORATORY MEDICINE, 2002, 22 (04) : 963 - +
  • [12] The chimpanzee and other non-human-primate models in HIV-1 vaccine research
    Nath, BM
    Schumann, KE
    Boyer, JD
    TRENDS IN MICROBIOLOGY, 2000, 8 (09) : 426 - 431
  • [13] HIV-1 vaccine immunogen design strategies
    Mann, Jaclyn K.
    Ndung'u, Thumbi
    Virology Journal, 2015, 12
  • [14] HIV-1 vaccine immunogen design strategies
    Jaclyn K Mann
    Thumbi Ndung’u
    Virology Journal, 12
  • [15] AIDS - Diversity considerations in HIV-1 vaccine selection
    Gaschen, B
    Taylor, J
    Yusim, K
    Foley, B
    Gao, F
    Lang, D
    Novitsky, V
    Haynes, B
    Hahn, BH
    Bhattacharya, T
    Korber, B
    SCIENCE, 2002, 296 (5577) : 2354 - 2360
  • [16] Selection of HIV-1 subtype A phage libraries for HIV preventive vaccine development
    Galkin, A. N.
    Soloviev, A. I.
    Kiselev, S. M.
    Gagarina, E. Y.
    Bychenko, A. B.
    Filinova, E. Y.
    VACCINE, 2008,
  • [17] IMMUNOGENICITY AND TOXICITY TESTING OF AN EXPERIMENTAL HIV-1 VACCINE IN NONHUMAN-PRIMATES
    NEWMAN, MJ
    WU, JY
    COUGHLIN, RT
    MURPHY, CI
    SEALS, JR
    WYAND, MS
    KENSIL, CR
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (08) : 1413 - 1418
  • [18] Parameter Estimation and Identifiability of a HIV-1 Model
    Portelo, A.
    Lemos, J. M.
    Vinga, S.
    Ribeiro, Ruy M.
    Cruz, J. P.
    Valadas, E.
    2013 21ST MEDITERRANEAN CONFERENCE ON CONTROL AND AUTOMATION (MED), 2013, : 691 - 696
  • [19] Analysis of nonhuman primate peripheral blood mononuclear cells for susceptibility to HIV-1 infection and HIV coreceptor expression
    Benton, PA
    Timanus, DK
    Shearer, MH
    White, GL
    Lee, DR
    Kennedy, RC
    DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 1999, 23 (01): : 97 - 105
  • [20] Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy
    Julg, Boris
    Stephenson, Kathryn E.
    Tomaka, Frank
    Walsh, Stephen R.
    Tan, C. Sabrina
    Lavreys, Ludo
    Sarnecki, Michal
    Ansel, Jessica L.
    Kanjilal, Diane G.
    Jaegle, Kate
    Speidel, Tessa
    Nkolola, Joseph P.
    Borducchi, Erica N.
    Braams, Esmee
    Pattacini, Laura
    Burgess, Eleanor
    Ilan, Shlomi
    Bartsch, Yannic
    Yanosick, Katherine E.
    Seaman, Michael S.
    Stieh, Daniel J.
    van Duijn, Janine
    Willems, Wouter
    Robb, Merlin L.
    Michael, Nelson L.
    Walker, Bruce D.
    Pau, Maria Grazia
    Schuitemaker, Hanneke
    Barouch, Dan H.
    NPJ VACCINES, 2024, 9 (01)